Typhoid conjugate vaccine implementation in India: A review of supportive evidence
Background: Typhoid conjugate vaccines are available in the private market in India and are also recommended by the National Technical Advisory Group on Immunisation (NTAGI) for inclusion in India’s Universal Immunisation Programme in 2022 to control and prevent typhoid fever. Our study aims to synt...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136224001414 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850178274686140416 |
|---|---|
| author | Vijayalaxmi V. Mogasale Anish Sinha Jacob John Habib Hasan Farooqui Arindam Ray Tracey Chantler Vittal Mogasale Bhim Gopal Dhoubhadel W John Edmunds Andrew Clark Kaja Abbas |
| author_facet | Vijayalaxmi V. Mogasale Anish Sinha Jacob John Habib Hasan Farooqui Arindam Ray Tracey Chantler Vittal Mogasale Bhim Gopal Dhoubhadel W John Edmunds Andrew Clark Kaja Abbas |
| author_sort | Vijayalaxmi V. Mogasale |
| collection | DOAJ |
| description | Background: Typhoid conjugate vaccines are available in the private market in India and are also recommended by the National Technical Advisory Group on Immunisation (NTAGI) for inclusion in India’s Universal Immunisation Programme in 2022 to control and prevent typhoid fever. Our study aims to synthesise the supportive evidence for typhoid conjugate vaccine implementation in the routine immunisation programme of India. Methods: We conducted a literature review to identify supportive evidence for typhoid conjugate vaccine implementation in India based on the key criteria of the World Health Organisation’s Evidence-to-Recommendation framework for National Immunisation Technical Advisory Groups. Results: We synthesised evidence on typhoid disease burden, benefits and harms of typhoid conjugate vaccine, cost-effectiveness analysis, and implementation feasibility. However, the in-country evidence on budget impact analysis, vaccine demand and supply forecast, equity analysis, target population values and preferences, immunisation service providers’ acceptability, co-administration safety, and antimicrobial resistance tracking were limited. Conclusion: Based on the literature review, we identified evidence gaps. We recommend identifying research priorities for supporting typhoid conjugate vaccine implementation decision-making in India by combining evidence gaps with the perceived importance of the same evidence criteria and factors among immunisation stakeholders. |
| format | Article |
| id | doaj-art-884b82a3419d4ffb98d860d87e043bba |
| institution | OA Journals |
| issn | 2590-1362 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj-art-884b82a3419d4ffb98d860d87e043bba2025-08-20T02:18:47ZengElsevierVaccine: X2590-13622024-12-012110056810.1016/j.jvacx.2024.100568Typhoid conjugate vaccine implementation in India: A review of supportive evidenceVijayalaxmi V. Mogasale0Anish Sinha1Jacob John2Habib Hasan Farooqui3Arindam Ray4Tracey Chantler5Vittal Mogasale6Bhim Gopal Dhoubhadel7W John Edmunds8Andrew Clark9Kaja Abbas10Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical Medicine, London, UK; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan; Corresponding author at: Vijayalaxmi V Mogasale, Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical Medicine, London, UK.Indian Institute of Public Health-Gandhinagar, IndiaDepartment of Community Health, Christian Medical College, Vellore, IndiaCollege of Medicine, Qatar University, Doha, QatarDepartment of Infectious Disease & Vaccine Delivery, Bill and Melinda Gates Foundation, New Delhi, IndiaDepartment of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UKGraduate School of Public Health, Yonsei University, Seoul, Republic of Korea (Current affiliation: Health Financing and Economics Department, World Health Organisation, Geneva, Switzerland)School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan; Department of Clinical Medicine and Research, Institute of Tropical Medicine, Nagasaki University, Nagasaki, JapanDepartment of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical Medicine, London, UK; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan; Department of Infectious Disease Epidemiology and Dynamics, Institute of Tropical Medicine, Nagasaki University, Nagasaki, JapanDepartment of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UKDepartment of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical Medicine, London, UK; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan; Department of Infectious Disease Epidemiology and Dynamics, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan; Public Health Foundation of India, New Delhi, IndiaBackground: Typhoid conjugate vaccines are available in the private market in India and are also recommended by the National Technical Advisory Group on Immunisation (NTAGI) for inclusion in India’s Universal Immunisation Programme in 2022 to control and prevent typhoid fever. Our study aims to synthesise the supportive evidence for typhoid conjugate vaccine implementation in the routine immunisation programme of India. Methods: We conducted a literature review to identify supportive evidence for typhoid conjugate vaccine implementation in India based on the key criteria of the World Health Organisation’s Evidence-to-Recommendation framework for National Immunisation Technical Advisory Groups. Results: We synthesised evidence on typhoid disease burden, benefits and harms of typhoid conjugate vaccine, cost-effectiveness analysis, and implementation feasibility. However, the in-country evidence on budget impact analysis, vaccine demand and supply forecast, equity analysis, target population values and preferences, immunisation service providers’ acceptability, co-administration safety, and antimicrobial resistance tracking were limited. Conclusion: Based on the literature review, we identified evidence gaps. We recommend identifying research priorities for supporting typhoid conjugate vaccine implementation decision-making in India by combining evidence gaps with the perceived importance of the same evidence criteria and factors among immunisation stakeholders.http://www.sciencedirect.com/science/article/pii/S2590136224001414Typhoid feverTyphoid conjugate vaccineEvidence-to-RecommendationIndiaImplementation |
| spellingShingle | Vijayalaxmi V. Mogasale Anish Sinha Jacob John Habib Hasan Farooqui Arindam Ray Tracey Chantler Vittal Mogasale Bhim Gopal Dhoubhadel W John Edmunds Andrew Clark Kaja Abbas Typhoid conjugate vaccine implementation in India: A review of supportive evidence Vaccine: X Typhoid fever Typhoid conjugate vaccine Evidence-to-Recommendation India Implementation |
| title | Typhoid conjugate vaccine implementation in India: A review of supportive evidence |
| title_full | Typhoid conjugate vaccine implementation in India: A review of supportive evidence |
| title_fullStr | Typhoid conjugate vaccine implementation in India: A review of supportive evidence |
| title_full_unstemmed | Typhoid conjugate vaccine implementation in India: A review of supportive evidence |
| title_short | Typhoid conjugate vaccine implementation in India: A review of supportive evidence |
| title_sort | typhoid conjugate vaccine implementation in india a review of supportive evidence |
| topic | Typhoid fever Typhoid conjugate vaccine Evidence-to-Recommendation India Implementation |
| url | http://www.sciencedirect.com/science/article/pii/S2590136224001414 |
| work_keys_str_mv | AT vijayalaxmivmogasale typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence AT anishsinha typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence AT jacobjohn typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence AT habibhasanfarooqui typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence AT arindamray typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence AT traceychantler typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence AT vittalmogasale typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence AT bhimgopaldhoubhadel typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence AT wjohnedmunds typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence AT andrewclark typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence AT kajaabbas typhoidconjugatevaccineimplementationinindiaareviewofsupportiveevidence |